CI

At a glance

ClinicalIndex Comparison Record
N/ACompleted· 90 enrolled
Drug / intervention
Bupivacaine 0.25% +1 moredrug
Likely dose
Bupivacaine 0.25% 40 mLfrom record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT07030647
NCT07030647N/ACompleted

Efficacy of the Analgesic Effect of Local Anesthetic Injection on Postoperative Pain in Gynecological Laparoscopic Surgeries: A Randomized Controlled Trial

Usama Ahmed Elsaeed Salem, MD·interventional·Posted Jun 22, 2025·Updated Jun 22, 2025

In Brief

A clinical study evaluating Bupivacaine 0.25% for Gynecologic Laparoscopic Surgery and 3 related conditions. Completed, enrolled 90 participants across 1 site.

Detailed Summary

This is a randomized, double-blind, controlled clinical trial evaluating the efficacy of local anesthetic (LA) in reducing postoperative pain in patients undergoing gynecologic laparoscopic surgery. Ninety participants will be randomly assigned into three equal groups: Group A will receive LA injection at the port site, Group B will receive intraperitoneal LA injection, and Group C will serve as the control group with no LA intervention. Postoperative pain will be assessed and compared among the three groups.

Study Details

Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
CountriesEgypt
Collaborators--

Timeline

N/ACompletedFinished
20252026
First PostedJun 22, 2025
Enrollment StartMar 1, 2024
Primary CompletionFeb 5, 2025
Study CompletionMar 30, 2025
TodayJul 2, 2026
Enrollment to primary: 11 monthsPosted 1.0 years ago

Interventions

Bupivacaine 0.25%drug

At the end of gynecologic laparoscopic surgery and prior to trocar removal, 40 mL of Bupivacaine 0.25% is instilled intraperitoneal under direct vision to evaluate its analgesic effect.

Bupivacaine 0.25%drug

Before trocar insertion in gynecologic laparoscopic surgery, 5 mL of Bupivacaine 0.25% is infiltrated subcutaneously at each trocar port site to assess its effect on postoperative pain.